Analyst Price Target is $5.00
▲ +226.80% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for OKYO Pharma in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 226.80% upside from the last price of $1.53.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in OKYO Pharma. This Buy consensus rating has held steady for over two years.
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.